St Jude Medical Inc (STJ) SEC Filing 10-K Annual report for the fiscal year ending Saturday, January 2, 2016

Exhibit 99.1

News Release

St. Jude Medical Reports Fourth Quarter and Full-Year 2015 Results

ST. PAUL, Minn. – Jan. 27, 2016 – St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings for the fourth quarter and full-year ended Jan. 2, 2016.

Fourth quarter 2015 highlights:

·                  Neuromodulation sales increased 9 percent on a constant-currency basis over the fourth quarter of 2014

·                  Thoratec product sales grew 15% on a comparable constant currency basis for the full fourth quarter 2015

·                  Adjusted net earnings per share of $1.02 increased 11 percent on a constant currency basis, compared to the fourth quarter of 2014

Fourth Quarter and Full-Year 2015 Sales

The company reported net sales of $1.447 billion in the fourth quarter of 2015, a 1 percent increase over net sales of $1.439 billion in the fourth quarter of 2014. On a constant-currency basis, net sales increased by 7 percent over the fourth quarter of 2014.

Fourth quarter sales of Thoratec products were $136 million driven by continued strength in the U.S. and the launch of Heartmate 3™ Left Ventricular Assist System in Europe. Full fourth quarter 2015 Thoratec sales of $143 million represent comparable constant currency quarterly sales growth of 15% over fourth quarter 2014 sales of $128 million.

When comparing net sales for the full fourth quarter of 2015 to the combined net sales of both St. Jude Medical and Thoratec for the fourth quarter of 2014 and adjusting for foreign currency, comparable constant currency sales decreased 1 percent.

For the full-year 2015, net sales were $5.541 billion, compared with $5.622 billion in 2014. On a constant-currency basis, net sales increased 6 percent over the prior year. When comparing net sales for the full year 2015 to the combined net sales of both St. Jude Medical and Thoratec for the full-year 2014 and adjusting for foreign currency, comparable constant currency sales increased 4 percent.

Commenting on the company’s financial results, St. Jude Medical President and Chief Executive Officer Michael T. Rousseau said, “We are pleased with the momentum we achieved in 2015 in our atrial fibrillation, heart failure and neuromodulation businesses and with the significant progress we have made integrating Thoratec, which had a strong fourth quarter. In 2016, we expect to continue our focus on these key areas which will drive our growth and allow us to deliver a comprehensive portfolio of innovative technologies to patients around the world.”